-
Chinese vice-premier calls for boosting basic pharmaceutical research, sci-tech innovation
2025-07-11
Liu, also a member of the Political Bureau of the Communist Party of China Central Committee, visited Peking University's School of Pharmaceutical Sciences to learn about medical research and development, as well as the construction and operations of key laboratories, and listened to opinions from various relevant parties at a symposium.
-
Li Li meets with head of Uzbekistan’s Center for Safety of Pharmaceutical Products
2025-07-03
Li Li, commissioner of China's National Medical Products Administration (NMPA), met with a delegation led by Alisher Temirov, acting director of the Center for the Safety of Pharmaceutical Products of the Ministry of Health of Uzbekistan, in Beijing on June 27.
-
NMPA holds meeting to review QMS in vaccine regulation, pharmaceutical manufacturing inspection
2025-06-16
The National Medical Products Administration (NMPA) held a meeting on June 9 to conduct the 2024 annual review of the quality management system (QMS) in vaccine regulation and pharmaceutical manufacturing inspection.
-
NMPA Announcement on Further Improvement and Optimization of Matters Concerning the Production of Imported Medical Devices in Domestic Enterprises in China (No. 30, 2025)
2025-06-11
To thoroughly implement the decisions of the CPC Central Committee and the State Council on advancing high-level opening-up, fully carry out the requirements of the Opinions of the General Office of the State Council on Comprehensively Deepening the Regulatory Reform of Drugs and Medical Devices to Promote the High-Quality Development of the Pharmaceutical Industry (GBF [2024] No. 53), continuously deepen the reform of medical device regulation, and promote the high-quality development of the medical device industry, the following adjustments and optimizations are hereby made to certain provisions of the Announcement.
-
NPMA Announcement on Expanding the Implementation Scope of Electronic Common Technical Documents (No.10, 2025)
2025-06-11
To accelerate the implementation process of the Electronic Common Technical Document (eCTD) in China and enhance the service capabilities of "Internet + Drug Regulation" applications, the following matters concerning the expansion of the eCTD implementation scope are hereby announced.
-
Netanasvir Phosphate Capsules Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1 innovative drug Netanasvir Phosphate Capsules (trade name: 东卫卓/Dongweizhuo) of Sunshine Lake Pharma Co., Ltd. is approved for marketing by China NMPA.
